ASH: Bristol Myers' Breyanzi, Gilead's Yescarta lock horns in race to move CAR-T therapy to earlier lymphoma

Gilead’s Yescarta appears to have an upper hand in the battle for CAR-T supremacy, given its three-year head start over Bristol’s Breyanzi. In a recent survey Cowen conducted with 20 lymphoma-treating doctors after BMS and Gilead had touted their second-line wins, 60% of oncologists chose Yescarta or Gilead’s newer Tecartus as their likely favored CD19 CAR-T product in 2024. Breyanzi was selected by 25% of doctors, the analysts said.